Sub Navigation
Patent on "Breast Cancer Gene 2" patent maintained in amended form after public hearing
Munich, 29 June 2005 - An opposition division of the European Patent Office (EPO) has decided that European patent EP 785216 is to be maintained in amended form.
Following a public hearing involving all parties to opposition proceedings against the patent, the opposition division competent in the case - a panel consisting of three patent examiners - has concluded that the contested patent can be maintained in amended form.
The patent claim now relates to the use of a particular nucleic acid carrying a mutation of the BRCA 2-gene which is associated with a predisposition to breast cancer for in vitro-diagnosing of such a predisposition in Ashkenazi-Jewish women.
The opposing parties to the proceedings are entitled to challenge the opposition division's decision in second-instance proceedings before one of the EPO's technical boards of appeal.
The full reasons for the decision will be set out in writing and published as soon as possible; they will also be made available online and will then be open to consultation at www.epoline.org as part of the EPO's public file inspection service.